Endocrine Abstracts

Background: SGLT2-I is a promising new class of diabetes pharmacotherapy, it targets blood glucose lowering in both postprandial and fasting states. It offers minimal risk of hypoglycemic events and demonstrates modest effects on blood pressure and weight.Objective: Meta-analysis review of SGLT2-I outcome, safety and efficacy RCT.Methods: Medline, EMBASE & CENTRAL were searched until August 2015, double blind RCT in T2DM with a...

A comprehensive pregestational prenatal monitoring and early detection of diabetes amongst pregnant patients is the cornerstone of the updated ADA recommendation 2016 in Diabetes Care.It is our main objective to lay out an attainable management plan for early diagnosis, and management of gestational diabetic in a community clinic.The plan includes implementation of family planning and effective contraception for known women with pr...

The primary objective of this study is to examine the monetary and associated costs of diabetes in the state of Texas and the factors involved.The growing rates of obesity and associated diabetes continue to be a burden on the healthcare system. Data gathered from state records is reviewed and summarized by investigators to determine the fiscal cost of managing diabetes medically from the state and Medicaid/medicare, and also the associated costs of pati...

Background: C-peptide therapy ameliorates sensory nerve function in T1DM neuropathy. Prolonged GLUT-4 translocation and delayed counter regulation can induce hypoglycemia. GLUT-2 protein is the primary hepatic liver transporter related to hepatic glucose regulation it also plays a role on glucose sensing by pancreatic beta cells, via hepatoportal sensors controlling the autonomic nervous system and stimulates glucagon secretion.Objective: To discuss the ...

Background: Oral semaglutide GLP1 receptor agonist is coformulated for better absorption compared to prior injectable semaglutide. Phase 2 open label, dose escalation randomized clinical trials of semaglutide and liraglutide investigating the dose-response relationship between the two. DPP-4 inhibitor produces a smaller glycemic reduction and minimal weight reduction through effect of endogenous GLP-1 receptor activity, while GLP-1RAs yield greater efficacy related to the phar...